Home > Latest News > Two projects gain HTC Incubator funding

Two projects gain HTC Incubator funding

Two new projects have been awarded grants through the HTC’s Incubator Funding Programme, aimed at supporting early stage technologies in the areas of nanotechnology, robotics and imaging which target unmet clinical needs.

Professor David Cumming, of the University of Glasgow, has been given funding to help develop his wireless fluorescence imaging capsule for use in endoscopy, to help improve identification of tumours, bleeding and Crohn’s disease. Professor Cumming aims to use the funding to develop a network of clinical and industrial partners, who can help overcome the challenges associated with clinical trials of the technology and develop a road map to move the project towards commercial prototyping and commercial and clinical approval.

Dr Kate Ricketts, from University College London, will use her incubator grant to develop the use of metal nanoparticles in targeted radiotherapy and improved imaging for colorectal cancer. The aim is to create metal nanoparticles that will gravitate to cancerous tissue, to enhance the effect of radiotherapy treatment and enable surgeons to see the extent of the tumour more clearly. Dr Ricketts will use the funding to set up a workshop involving colorectal surgeons, colorectal cancer oncologists and radiation oncologists as well as clinical trials specialists and pharmaceutical companies, to help develop a roadmap to wider clinical take up of the technology.

As part of the grant award, the HTC will draw on its network of clinicians, academics and industry contacts to take part in the workshops, as well as facilitating and managing them on behalf of the researchers.

HTC Clinical Director, Professor David Jayne said: “These are both very promising technologies, which just need the right combination of knowledge and skills to help them move forward. The incubator workshops can provide that, by bringing together a mix of expertise to discuss the technology and develop a road map towards clinical trials and commercialisation.”